The adoptive cell therapy market involves the processing and engineering of immune cells isolated from a patient to target cancerous cells. The therapy involves extracting patients’ T cells or natural killer cells, modifying them through genetic engineering techniques and expanding their numbers before infusing them back into the patient’s body to identify and eliminate cancer cells. The therapy holds promise for treating various types of cancers as it utilizes the body’s own immune system to fight the disease with minimal side effects compared to chemotherapy.
The Global Adoptive Cell Therapy Market is estimated to be valued at US$ 6903.93 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period between 2024 to 2031.
Key Takeaways
Key players operating in the adoptive cell therapy market: Broadcom, Celeno Communications, Infineon Technologies, Espressif Systems Shanghai Co Ltd, GCT Semiconductor Inc., I&C Technology, Intel Corporation, MediaTek, Inc., Microchip Technology Inc. The key players are increasingly investing in research and development of enhanced cell therapy treatments for cancer.
Growing demand for personalized medicine is driving the demand for adoptive cell therapy. The therapy provides a precise targeted treatment approach against cancer with minimal side effects making it an attractive alternative to chemotherapy and radiation therapy.
Increasing incidence of cancer globally is further propelling the demand for adoptive cell therapy. The therapy is also gaining adoption in the Asia Pacific region owing to growing cancer burden and increasing investments by market players looking to tap the opportunities in emerging countries.
Market key trends
One of the key trends in the adoptive cell therapy market is the increasing research on T cell receptor (TCR) therapies. TCR therapy involves genetically modifying T cells to recognize specific antigens expressed by tumor cells. Companies are conducting extensive research to discover novel TCRs that can target various types of cancer antigens with highest selectivity and efficacy. This brings promise for developing targeted personalized TCR therapies against different cancers in the future. Furthermore, combination therapies utilizing TCR modified T cells along with checkpoint inhibitors are being explored to boost anti-tumor activity. Such ongoing research and developments are expected to drive significant growth of the adoptive cell therapy market between 2024-2031.
Porter’s Analysis
Threat of new entrants: New entrants face high entry barrier due to large R&D investment and clinical trial expenses required for adoptive cell therapy development.
Bargaining power of buyers: Buyers have medium bargaining power due to availability of substitute therapies but high treatment costs reduce bargaining power.
Bargaining power of suppliers: Suppliers have medium bargaining power as companies can shift to alternate sources of materials with minimal additional investment required.
Threat of new substitutes: Threat is low currently due to lack of other effective therapies for cancer but gene therapy poses a threat in long run.
Competitive rivalry: Intense as major players are involved in new product launches, acquisitions and partnerships to gain market share.
Geographical Regions
North America accounts for the largest share currently due to presence of major market players, rising cancer incidence and favorable reimbursement scenario.
Asia Pacific region is poised to witness fastest growth of Adoptive Cell Therapy Market Size during forecast period driven by growing healthcare expenditure, increasing cancer cases and expanding R&D activities by key players looking to tap unmet needs.
Porter’s Analysis
Threat of new entrants: New entrants face high entry barrier due to large R&D investment and clinical trial expenses required for adoptive cell therapy development.
Bargaining power of buyers: Buyers have medium bargaining power due to availability of substitute therapies but high treatment costs reduce bargaining power.
Bargaining power of suppliers: Suppliers have medium bargaining power as companies can shift to alternate sources of materials with minimal additional investment required.
Threat of new substitutes: Threat is low currently due to lack of other effective therapies for cancer but gene therapy poses a threat in long run.
Competitive rivalry: Intense as major players are involved in new product launches, acquisitions and partnerships to gain market share.
Geographical Regions
North America accounts for the largest share currently due to presence of major market players, rising cancer incidence and favorable reimbursement scenario.
Asia Pacific region is poised to witness fastest growth during forecast period driven by growing healthcare expenditure, increasing cancer cases and expanding R&D activities by key players looking to tap unmet needs.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it